secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001193125-26-045526
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Therapeutics releases corporate presentation at Guggenheim summit; no material details disclosed
--------------------------------------------------------------------------------

- Presentation dated February 2026 made available for Guggenheim Emerging Outlook: Biotech Summit.
- No financial results, pipeline updates, or guidance changes were provided in the filing.
- The filing is a routine Regulation FD disclosure with limited substantive news.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526045526/0001193125-26-045526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312526045526/nmra-20260211.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-045526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer